OPUS GENETICS INC
IRDNASDAQTrading Snapshot
- Day Range
- $4.92 – $5.01
- 52-Week Range
- $1.50 – $7.07
- Volume
- $3.82B
- Avg Volume
- $4.11B
- Shares Outstanding
- 82.6M
- Next Earnings
- Nov 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $14M
- Last Q Revenue
- $755,000
- P/E Ratio
- -3.9
- P/S Ratio
- 41.5x
- EPS (TTM)
- $-1.13
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1870.6%
Why Investors Own IRD
- ✓High-growth profile — revenue up +30.9% YoY with expanding US Equity exposure.
- ✓Healthy economics — 77% gross margin and 9% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
OPUS GENETICS INC
IRD
StockOtter · stockotter.spaceAbout OPUS GENETICS INC
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
Squarepoint Ops LLC Takes $1.36 Million Position in Opus Genetics, Inc. $IRD
Squarepoint Ops LLC purchased a new stake in Opus Genetics, Inc. (NASDAQ: IRD) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purcha
Opus Genetics: A Resounding Study Success Merits A Higher Valuation
Opus Genetics receives a Buy rating following >30% stock surge on positive Phase 1/2 data for OPGx-BEST1 in BEST1-related retinal diseases. OPGx-BEST1 showed clinically meaningful visual improvements and strong safety in
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
Opus Genetics, Inc. (IRD) Discusses Topline Results From Cohort 1 of BEST1 Phase I/II Gene Therapy Trial Transcript
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
Opus Genetics, Inc. (NASDAQ:IRD) stock is surging on Wednesday after the company reported positive three- and six-month results from the low-dose first cohort of its Phase 1/2 BIRD-1 trial of OPGx-BEST1.
Opus Genetics Announces Positive Low Dose Cohort 1 Data from Phase 1/2 Clinical Trial of OPGx-BEST1 and Successful FDA Type C Meeting with Potential Phase 3 Dosing in 2027
OPGx-BEST1 demonstrated a favorable safety and tolerability profile with no serious adverse events or dose-limiting toxicities observed All five participants demonstrated clinically meaningful improvement in visual func
Analysts Set Opus Genetics, Inc. (NASDAQ:IRD) PT at $10.69
Opus Genetics, Inc. (NASDAQ: IRD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the eighteen analysts that are presently covering the firm, MarketBeat Ratings reports. One equities rese